Bristol-myers squibb stock.
The Bristol Myers Squibb 52-week high stock price is 81.42, which is 62.5% above the current share price. The Bristol Myers Squibb 52-week low stock price is 48.25, which is 3.7% below the current share price. The average Bristol Myers Squibb stock price for the last 52 weeks is 64.65. For more information on how our historical price data is ...
Dividend History Summary. Bristol Myers Squibb (BMY) announced on September 20, 2023 that shareholders of record as of October 5, 2023 would receive a dividend of $0.57 per share on November 1 ...Get Bristol-Myers Squibb Co (BMY.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsBristol-Myers Squibb Co Bristol-Myers Squibb Co BMY Morningstar Rating Unlock Stock XNYS Rating as of Nov 29, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns...Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Get the latest information on Bristol-Myers Squibb Company (BMY) stock, including its performance, earnings, dividends, and outlook. See the company's ratings, research reports, news, and related articles from Yahoo Finance and Morningstar.
Contact Bristol Myers Squibb through our contact form, customer relations line or live chat. For product side-effect inquiries call (800) 721-5072. ... Stock split history > Investment return calculator > SEC filings > Quarterly Results > Product Sales summary > …
Aug 29, 2022 · Bristol Myers Squibb (BMY-0.41%) stock was down by a noteworthy 5.4% as of 1:32 p.m. ET Monday afternoon. Bristol's share price is in retreat mode today after the company announced over the ...
Summary. I expected Bristol-Myers Squibb Company stock to keep rising in value through 2023 and perhaps reach triple figures. Instead, the share price has fallen 5% this year as inflationary ...Key statistics. Bristol-Myers Squibb Co (BMY:NYQ) set a new 52-week low during today's trading session when it reached 48.25. Over this period, the share price is down -39.13%. Data delayed at least 15 minutes, as of Nov 30 2023 16:26 GMT. Latest Bristol-Myers Squibb Co (BMY:NYQ) share price with interactive charts, historical prices ...Combining Bristol-Myers Squibb's Debt And Its 29% Return On Equity Bristol-Myers Squibb clearly uses a high amount of debt to boost returns, as it has a debt to equity ratio of 1.30.PRINCETON - Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 CheckMate -67T noninferiority trial evaluating the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme's proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as 'subcutaneous nivolumab') compared to …Get Bristol-Myers Squibb Co (BMY) real-time stock quotes, news, ... Bristol-Myers Squibb Co BMY. Official Data Partner. Latest Trade. trading higher 49.76 USD. Change 0.34 % Change
Bristol Myers Squibb Co. analyst ratings, historical stock prices, earnings estimates & actuals. BMY updated stock price target summary.
Bristol-Myers Squibb's stock is down 40% despite a market increase of 20%. Read here why we think BMY may be undervalued.
Discover historical prices for BMY stock on Yahoo Finance. View daily, weekly or monthly format back to when Bristol-Myers Squibb Company stock was issued. What is the 52-Weeks High and Low Range of Bristol-Myers Squibb Co. As on 01 Dec 2023 09:30, the 52-week high range for Bristol-Myers Squibb Co. share is $81.42 ...Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company. The dividend is payable on November 1, 2021 to stockholders of record at the close of business on October 1, 2021. In addition, the Board …Bristol-Myers Squibb Company (BMY) dividend yield: annual payout, 4 year average yield, yield chart and 10 year yield history.Fiscal Q3 2023 ended 9/30/23. Reported on 10/25/23. Get the latest Bristol-Myers Squibb Co (BMY) real-time quote, historical performance, charts, and other financial information …Bristol-Myers Squibb insiders own about US$63m worth of shares. That equates to 0.06% of the company. This level of insider ownership is good but just short of being particularly stand-out.Nov 20, 2023 · Bristol-Myers Squibb (NYSE: BMY) stock is falling on Monday after a couple of updates that are weighing on BMY shares today. The first bit of news worth noting is the results from a clinical trial ...
Sep 28, 2023 · Bristol-Myers was an $80 stock towards the end of 2022 and now the stock sits below $60. The biopharma had just guided to 2022 EPS of $7.44 to $7.74 per share for 2022 when the rally to $80 occurred. Bristol-Myers Squibb Company published this content on 29 April 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 29 April 2022 13:56:04 UTC .On Oct. 8, Bristol Myers announced plans to acquire Mirati Therapeutics. Under the merger agreement, it will cost up to $5.8 billion ($1 billion is contingent on the approval of a new drug ...Aug 29, 2022 · Bristol Myers Squibb (BMY-0.41%) stock was down by a noteworthy 5.4% as of 1:32 p.m. ET Monday afternoon. Bristol's share price is in retreat mode today after the company announced over the ... 2 days ago · Bristol-Myers Squibb stock has received a consensus rating of hold. The average rating score is and is based on 20 buy ratings, 21 hold ratings, and 11 sell ratings. What was the 52-week low for ... Stock split history for Bristol-Myers Squibb (BMY) Bristol-Myers Squibb stock (symbol: BMY) underwent a total of 6 stock splits. The most recent stock split occured on August 7th, 2001. One BMY share bought prior to May 31st, 1977 would equal to 33.621320960687 BMY shares today. Stock split list. DateCompared to the current market price of 49.835 USD , Bristol-Myers Squibb Co is Undervalued by 45%. ALPHA SPREAD. Join 87,600+ value investors using Alpha Spread. Create a free account. or see our plans & pricing. Bristol-Myers Squibb Co (NYSE:BMY) Intrinsic Valuation. Check if BMY is overvalued or undervalued under the bear, base, and …
Bristol-Myers Squibb Co Bristol-Myers Squibb Co BMY Morningstar Rating Unlock Stock XNYS Rating as of Nov 29, 2023 Summary Chart News Price vs …
Bristol Myers Squibb ( BMY -1.49%) stock was down by a noteworthy 5.4% as of 1:32 p.m. ET Monday afternoon. Bristol's share price is in retreat mode today after the company announced over the ...The pharma giant says that on completion of the acquisition, Celgene is now a wholly owned subsidiary of Bristol-Myers Squibb Company, and that under the terms of the merger, Celgene shareholders received for each share, 1.00 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest, as well as one tradeable …BMY) stock’s latest price update. The stock of Bristol-Myers Squibb Co. (NYSE: BMY) has increased by 1.46 when compared to last closing price of 49.38.Despite this, the company has seen a gain of 0.68% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-29 that The FDA has undertaken an investigation ...Complete Bristol Myers Squibb Co. stock information by Barron's. View real-time BMY stock price and news, along with industry-best analysis. Bristol-Myers Squibb (BMY 1.46%) is a top healthcare company with a rich history that goes back to the 1800s. But its business, and its stock, have been underperforming recently.Bristol Myers Squibb Co. analyst ratings, historical stock prices, earnings estimates & actuals. BMY updated stock price target summary.According to the issued ratings of 18 analysts in the last year, the consensus rating for Bristol-Myers Squibb stock is Hold based on the current 1 sell rating, 13 hold ratings and 4 buy ratings for BMY. The average twelve-month price prediction for Bristol-Myers Squibb is $63.59 with a high price target of $85.00 and a low price target of $50. ...
Nov 20, 2023 · Bristol-Myers Squibb (NYSE: BMY) stock is falling on Monday after a couple of updates that are weighing on BMY shares today. The first bit of news worth noting is the results from a clinical trial ...
Find the latest historical data for Bristol-Myers Squibb Company Common Stock (BMY) at Nasdaq.com.
26 thg 10, 2022 ... Bristol Myers Squibb CEO Dr. Giovanni Caforio joins CNBC's 'Squawk on the Street' to discuss the company's third-quarter earnings report.In the latest trading session, Bristol Myers Squibb (BMY) closed at $65.04, marking a -0.4% move from the previous day. This change was narrower than the S&P 500's daily loss of 0.77%.NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2022, which reflect robust growth of the in-line and new product portfolios, driven by strong commercial execution and continued progress of the company's pipeline. “2022 was a successful year for our company, one of …Bristol-Myers Squibb stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.Get the latest information on Bristol-Myers Squibb Company (BMY) stock, including its performance, earnings, dividends, and outlook. See the company's ratings, research reports, news, and related articles from Yahoo Finance and Morningstar. Moreover, with a price of $48.86 and a GuruFocus Value of $71.94, Bristol-Myers Squibb Co has a price-to-GF-Value ratio of 0.68. This indicates that the stock is Significantly Undervalued based on ...Based on the closing price of Bristol-Myers Squibb stock of $52.43 on January 2, 2019, the cash and stock consideration to be received by Celgene shareholders at closing is valued at $102.43 per Celgene share and one CVR (as …Discover historical prices for BMY stock on Yahoo Finance. View daily, weekly or monthly format back to when Bristol-Myers Squibb Company stock was issued. A number of drug patents expired in 2022, including Bristol Myers Squibb’s Revlimid, Roche’s Lucentis, and AbbVie’s Restasis. The pharma industry in 2023 is set to face further shake-ups, many more blockbuster drugs from Johnson & Johnson, AbbVie, Roche and other companies are set to face their first generic or biosimilar competitors in …The latest price target for Bristol-Myers Squibb ( NYSE: BMY) was reported by Cantor Fitzgerald on Wednesday, November 15, 2023. The analyst firm set a price target for 55.00 expecting BMY to rise ...
9 thg 2, 2022 ... Approximately 85 percent of the shares to be repurchased under the ASR transactions will be received by Bristol-Myers Squibb on February 9, 2022 ...34,300. Chris Boerner. https://www.bms.com. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s …Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q4 2022 results on Thursday, February 2. We expect BMY stock to trade sideways, with its revenue falling marginally below, but earnings ...Instagram:https://instagram. gld stocbest tax free money market fundssolid state battery companyclf ticker Bristol-Myers Squibb Co Bristol-Myers Squibb Co BMY Morningstar Rating Unlock Stock XNYS Rating as of Nov 29, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns... usb stocksbest books for trading Quick links. At Bristol Myers Squibb, we work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to … xrx dividend Bristol-Myers Squibb's stock is down 40% despite a market increase of 20%. Read here why we think BMY may be undervalued.3 thg 1, 2019 ... Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene.